Kornimate/medical-research-clean huggingface dataset:
effect of olopatadine on allergic tear mediators

Conditions: Allergic Conjunctivitis

Summary: the purpose of the research is to determine which inflammatory substances are involved in causing allergic symptoms in the eye. allergic conjunctivitis is a common problem with symptoms of temporary redness, itching, tearing, and swelling of the eyes. substances released by cells in the affected tissues cause allergic reactions in the eye and elsewhere in the body.

ocular allergies are extremely common, affecting up to 80 million people in the usa. our research question is: are there differences in inflammatory mediators and cell surface activation markers in patients undergoing seasonal allergic conjunctivitis compared to those with sight threatening disease such as atopic keratoconjunctivitis (akc) and will the use of the anti-allergy eye drop, patanol® (olopatadine hydrochloride) affect these parameters? experimental design: ocular surface cells (by impression cytology) and tears (via capillary tube) are collected from allergic, non-allergic, and akc subjects undergoing an reaction induced either by seasonal allergen or topical allergen provocation (specificity and dose determined via skin testing). ocular surface cells are evaluated for surface activation markers. tears are evaluated for mediator content. tears are also incubated with peripheral blood eosinophils and lymphocytes to see effects on adhesion to conjunctival epithelial cells.

Eligibility criteria:
inclusion criteria: * skin test positive * able to put drops in eyes * able to have tears collected

Keywords: tears conjunctival epithelial cells olopatadine eosinophils
acute physiological and perceptual responses to novel forms of high-intensity interval exercise

Conditions: High-intensity Interval Exercise; Heart Rate; Rating of Perceived Exertion; Blood Pressure; Acute Mood; Physical Activity Enjoyment

Summary: randomised cross-over study seeking to explore the acute physiological and perceptual responses to three novel forms of high-intensity interval training (hit).

randomised cross-over study seeking to explore the acute physiological (heart rate and blood pressure) and perceptual responses (rating of perceived exertion, mood and enjoyment) to three novel forms (non-contact boxing, stair stepping and stair climbing) of high-intensity interval training (hit).

Eligibility criteria:
inclusion criteria: * adult (≥18 years) employees * no health conditions that preclude them from exercise and on no medication, information obtained via their self-report. * able to understand written and spoken english. * participants reporting that they are asthmatic will allowed to participate with medical clearance and instructed to bring their bronchodilator medication and use it when required. exclusion criteria: * symptoms of or known presence of heart disease * condition or injury or co-morbidity affecting the ability to undertake exercise * diabetes mellitus * early family history of sudden cardiac death * pregnancy or likelihood of pregnancy.
bridging recovery allies in virtual environments

Conditions: Traumatic Brain Injury

Summary: the bridging recovery allies in virtual environments (brave) study aims to evaluate the acceptability and feasibility of implementing a virtual environment (ve) social support group for social communication training among adults with traumatic brain injury (tbi).


Eligibility criteria:
inclusion criteria: * subjects with a traumatic brain injury * between the age of 18 and 80 * living in the community * able to read and speak english, * are more than 1-year post-injury * are accessible by phone, * report independent computer usage over the last 6 months * have access to a computer meeting minimum specifications for the learning in virtual environments (live) platform (requires windows) * have broadband internet connection, * achieve a galveston orientation assessment test (goat) score \>75 to ensure appropriate levels of cognition for the study * and score \>93.8 on the western battery aphasia-revised (wab-r) scale to indicate sufficient communicative abilities to participate in a social support group and exit interview group. * able to understand and independently consent for the study and provide written consent prior to enrollment in the study exclusion criteria: - verbal communication impairments will be excluded as measured by the wab-r, as this study intends to focus on persons with social communication deficits rather than verbal deficits.

Keywords: virtual environments social communication
platelet-rich plasma vs. hyaluronic acid for glenohumeral osteoarthritis

Conditions: Osteoarthritis; Shoulder Pain

Summary: this study seeks to expand the current literature in demonstrating potentially efficacious, conservative treatments in the management of glenohumeral osteoarthritis (oa) and will compare ultrasound-guided injections of hyaluronic acid vs. platelet-rich plasma. we aim to obtain information measuring potential benefits of these interventions and to observe for any adverse events.

glenohumeral oa accounts for approximately 2-5% of all chronic shoulder pain and may be classified into primary and secondary forms. primary glenohumeral oa is caused by degenerative joint disease, inflammatory arthropathies, and neuropathic arthropathy secondary to syringomyelia or diabetes. secondary glenohumeral oa is caused by trauma, postoperative changes after arthroscopy or capulorraphy, and osteonecrosis. hyaluronic acid is found in synovial joint fluid and has viscoelastic, chondroprotective, and possibly anti-inflammatory properties. it has been shown to increase joint lubrication. platelet-rich plasma contains growth factors that have been shown to promote tissue regeneration. the aim of this study is to determine whether injections of hyaluronic acid or platelet-rich plasma can be used reliably to decrease pain, restore function, and improve quality of life in patients suffering from glenohumeral oa. patients will be randomized to receive either an injection of hyaluronic acid or an injection of platelet-rich plasma. outcomes will be assessed via questionnaires for up to 52 weeks post-procedure.

Eligibility criteria:
inclusion criteria: * english speaking/literate * age 18-100 years * visual analog score pain \>= 5 * greater than or equal to 3 months of pain after onset of symptoms that has failed conservative treatments * confirmation of glenohumeral oa via routine imaging (mri and x-ray; must be recent and within the past year) * transient relief of symptoms after diagnostic intra-articular injection into the glenohumeral joint exclusion criteria: * non-english speaking/illiterate * painful active, concurrent cervical spine conditions * current non-steroidal anti-inflammatory drug (nsaid) use * history of taking coumadin or similar anticoagulant, have a known coagulopathy, bleeding dyscrasia, or platelet count \< 150,000/cubic mm * allergic reaction to poultry or previous viscosupplementation * involved in workers' compensation or active litigation involving affected shoulder * inability to refrain from nsaid use for 5 days prior to and 6 weeks after injection * history of corticosteroid injection to affected shoulder within the last 3 months * history of viscosupplementation or platelet-rich plasma to affected shoulder within the last 6 months * presence of acute fracture * history of shoulder tumor * known uncontrolled systemic illness (uncontrolled diabetes, human immunodeficiency virus, vasculitis, autoimmune/inflammatory disease) * psychiatric and somatoform disorders
psycho-education intervention for postpartum ocd and it's influence on symptom severity and treatment self referral rates

Conditions: Obsessive-Compulsive Disorder

Summary: the rationale for conducting the experiment including quantitative measures and a description of the method of recruitment: this study provides psycho-educational intervention aimed at raising awareness of post partum obsessive-compulsive disorder (ocd) , reducing the intensity of symptoms and increase of self referral to treatment. various studies report that 1-11% of women after childbirth suffer from ocd. a part of this population suffered from the disorder prior to giving birth and for some this is a first outbreak. this is a psychological disorder characterized by obsessions and compulsions. the disorder can appear or worsen at any time , and is characterized by different content depending on the stage of life. obsessional thoughts after birth often includes harming the baby which alarms the woman and the surrounding, and affects her ability to care for the baby and develop a beneficial relationship with him. studies support a bio-psycho-social model of ocd .and that adjustment period and physical changes after childbirth can be create a psychological biological and environmental background, to the development or worsening of ocd in women who suffer from or are prone to the disorder. the present study deals with psycho-educational information which will be given to women after birth who were identified as susceptible to develop ocd. the information will be delivered in the maternity ward through written and recorded data , and sent through the system qualtrics 4 weeks after birth. psycho-education is an important first step in cognitive behavioral therapy for ocd and may lead to anxiety reduction and commitment to treatment. the information sent in the study is similar to the information provided at the beginning of standard cognitive behavioral therapy.women will be recruited from the maternity ward at lis maternity hospital. in order to identify women at risk for ocd, all women in the maternity ward will be asked to fill a short questionnaire. women found at risk or as suffering from ocd will be invited to participate in the study.


Eligibility criteria:
inclusion criteria: * women are 48 hours after birth, meet the criteria for ocs (obsessive compulsive symptoms) or have previous history of ocd. * capable of filling computerized questionnaires. * capable of giving informed consent. exclusion criteria: * substance use
early carbon dioxide laser therapy for alleviation of incisional scar burden

Conditions: Skin Scarring

Summary: this is a prospective, randomized pilot study of patients who will undergo either early or late incisional laser therapy after breast reduction surgery to alleviate scar burden at nyu langone medical center. the purpose of this study is to see how well carbon dioxide (co2) laser therapy works at preventing scar formation after surgery.co2 laser therapy is currently being used by dermatologists and plastic surgeons to help with scarring after acne and to rejuvenate the face; its benefits are now being explored by medical professionals in dermatology and cosmetic surgery to prevent scarring after surgery.


Eligibility criteria:
inclusion criteria: * patients of all ethnic origins will be considered, although certain ethnic groups will be preferentially excluded more than others such as black and south asian patients due to our exclusion criteria related to darker skin individuals (see below). * patients undergoing bilateral breast reduction surgery exclusion criteria: * males will be excluded from this study as male patients rarely undergo breast reduction surgery. when males do undergo breast reduction surgery for gynecomastia, it is often unilateral, and is performed with several techniques and incision types that are not typical employed during female breast reduction. thus, for this study, only female patients will be considered (see below). * any patient enrolled in this study who shows evidence of delayed wound healing, dehiscence, or post operative infection at the first post operative visit will be excluded * patients with darker skin (fitzpatrick iv and above), which is a well-known contraindication to laser therapy * pregnant patients * patients who have had prior breast surgery * patients who have had prior chest/breast irradiation * patients with the following diseases which interferes with wound healing: prior hypertrophic scarring/keloids, type i or type ii diabetes mellitus, autoimmune diseases/collagen vascular diseases * patients who are active smokers * patients using blood thinners that cannot be stopped * patients who have used aspirin within a week of the procedure date

Keywords: skin scarring keloids hypertrophic scars co2 laser therapy
to assess the safety and activity of gbr 830, compared to placebo, in adults with moderate-to-severe atopic dermatitis

Conditions: Atopic Dermatitis

Summary: the purpose of this study is to determine the effect of gbr 830 on biomarkers in atopic dermatitis to enable further studies in this indication.


Eligibility criteria:
inclusion criteria: * male or female, 18 years or older * atopic dermatitis involvement that of at least 10% body surface area exclusion criteria: * treatment with systemic corticosteroids within 4 weeks before randomization, and topical steroids, tacrolimus and/or pimecrolimus within 1 week before the randomization (except emollients, and mild steroids (class 6 or 7) * any cell-depleting agents including but not limited to rituximab: within 6 months prior to the baseline visit or until lymphocyte and cd 19+ lymphocyte counts return to normal, whichever is longer. other biologics: within 5 half-lives or 8 weeks prior to the baseline visit, whichever is longer. allergen immunotherapy within 6 months before the baseline visit. * patient with history of serious local infection and systemic infection patient with history or current evidence of diseases such as tuberculosis, malignant disease, other inflammatory or autoimmune disease or hiv or hepatitis b or c positive.
begin with the right patients with dual-inhibition action therapy through vytorin for newly diagnosed dyslipidemia patients (0653a-172)(completed)

Conditions: Hypercholesterolemia

Summary: the purpose of this study is to determine the safety and tolerability of ezetimibe/simvastatin in patients newly diagnosed with dyslipidemia.


Eligibility criteria:
inclusion criteria: * male or female patient, 20 through 79 years of age * newly diagnosed dyslipidemia patients including: 1) intermediate risk (\>2 risk factors) with total cholesterol level above 200 mg/dl or low density lipoprotein-c (ldl-c) level\> 130 mg/dlwho failed a 3-month diet control period, or 2) high risk patients with history of coronary artery disease or diabetes and having a total cholesterol\> 200 mg/dl or ldl-c level\> 130 mg/dl * willing to follow an national cholesterol education program (ncep) therapeutic lifestyle changes (tlc) or similar cholesterol-lowering diet for the duration of the study * female patients receiving hormone therapy (including hormone replacement therapy, and estrogen antagonist/agonist, or oral contraceptives) if maintained on a stable dose and regimen for at least 8 weeks prior to visit 1 and if willing to continue the same regimen throughout the study exclusion criteria: * women who are pregnant or lactating * has a history of cancer within the past 5 years (except for dermatological basal cell or squamous cell carcinoma) * patients hypersensitive to simvastatin or ezetimibe * any condition or situation which, in the opinion of the investigator, might pose a risk to the patient or confound the results of the study * history of mental instability, drug/alcohol abuse within the past 5 years, or major psychiatric illness not adequately controlled by pharmacotherapy * nephritic syndrome or other clinically significant renal disease resulting in impaired renal function, defined as serum creatinine ≧ 1.5 mg/dl * alanine aminotransferase (alt), and aspartate aminotransferase (ast) above 1.5 x upper limit of normal (uln) or with active liver disease * congestive heart failure (new york heart association (nyha) iii or iv), uncontrolled cardiac arrythmias, uncontrolled hypertension (systolic blood pressure (sbp) \>160 mm hg or diastolic blood pressure (dbp) \>100 mm hg), unstable angina pectoris or severe peripheral artery disease, or experienced myocardial infarction, coronary artery bypass surgery, angioplasty within 3 months * unstable diabetes mellitus patient (hemoglobin a1c (hba1c) \> 8.5%) or newly diagnosed (within 3 months) or a change in anti-diabetic pharmacotherapy within 3 months of screening * secondary dyslipidemia (e.g., hypothyroidism) * disorders of the hematologic, digestive, or central nervous systems including cerebrovascular disease and degenerative disease that would limit study evaluation or participation * history of active or chronic hepatobiliary disease or cholelithiasis but have not undergone cholecystectomy
dexamethasone for the prophylaxis of pain flare study

Conditions: Cancer

Summary: radiation treatment is often recommended as a safe and quick treatment that gives most people good relief from bone pain within a couple of weeks. however, some people can experience a short episode of increased pain (called a 'flare') a day or two after radiation treatment, that lasts about a day. the purpose of this sturdy is to find out if a medication called dexamethasone can help prevent pain flare as a result of radiation therapy.

of all people diagnosed with cancer, 25% will have their cancer come back and spread to the bones. this often results in significant pain and suffering. radiation treatment is often recommended as a safe and quick treatment that gives most people good relief from bone pain within a couple of weeks. however, some people can experience a short episode of increased pain called a flare a day or two after radiation treatment that lasts about a day. studies suggest that around a third of all people who receive radiation treatment to help pain from cancer in the bones will have a pain flare. this study is being done because it would be helpful to prevent extra bone pain from happening to people after they receive radiation treatments. the purpose of this study is to find out if a medication called dexamethasone can help prevent pain flare as a result of radiation therapy.

Eligibility criteria:
inclusion criteria: * documented bone metastases by radiological imaging * patients at least 18 years of age * written consent * kps ≥ 40 * baseline worst pain at the planned radiated bony metastatic site ≥ 2 * patient able to inform the pain score at the planned radiated bony metastatic site exclusion criteria: * concurrent use of any corticosteroid medication other than topical or inhaled preparations * medical contraindications to corticosteroids such as diabetes mellitus, uncontrolled hypertension or active peptic ulcer * pathological fracture of the irradiated extremity * spinal cord compression * language barrier * immediate change in regular analgesic medication. if the oncologist thinks the patient is not receiving adequate analgesic, we recommend the oncologist to increase the analgesic first to stabilize ot lessen the pain before recruiting the patient to this study

Keywords: radiation therapy palliative pain
effects of glucagon like peptide-1 on no-reflow

Conditions: Acute ST-segment Elevation Myocardial Infarction

Summary: the investigators planned to evaluate the effects of liraglutide on no-reflow in patients with acute st-segment elevation myocardial infarction (stemi).

acute myocardial infarction (ami) is a major cause of mortality and morbidity. primary percutaneous coronary intervention (pci) is currently the most effective treatment strategy for ami. brisk thrombolysis in myocardial infarction (timi) grade 3 flow immediately after pci in patients with ami is associated with improved clinical outcomes compared with lower flow grades. however, myocardial reperfusion is suboptimal in many patients, mostly because of the 'no-reflow' phenomenon. no-reflow is defined as suboptimal myocardial reperfusion in part of the coronary circulation without angiographic evidence of mechanical vessel obstruction. to date, however, very few drugs have been shown to reverse established no-reflow. glucagon-like peptide-1 (glp-1) is an incretin hormone that regulates plasma glucose, and glp-1 analogues were recently introduced for the treatment of acute myocardial infarction. glp-1 has antioxidant and anti-inflammatory properties, and may protect endothelial function. experimental studies have also revealed that glp-1 or its analogues protect against reperfusion injury in pigs. exenatide, a glp-1 analogue, was reported to reduce reperfusion injury in patients with st-segment elevation myocardial infarction. similarly, liraglutide was reported to reduce cardiac rupture and infarct size and improve cardiac output in normal and diabetic mice. to date, however, there is no clinical evidence for the effects of liraglutide on no-reflow in patients with ami. therefore, the aim of this study was to evaluate the effects of liraglutide pretreatment on myocardial no-reflow of prime pci in patients with ami.

Eligibility criteria:
inclusion criteria: patients with st-segment elevation myocardial infarction were eligible for the study. exclusion criteria: patients were excluded for the following reasons: unconscious at presentation; had cardiogenic shock, hypoglycaemia, or diabetic ketoacidosis; had a history of myocardial infarction, stent thrombosis, or renal insufficiency; or had previously undergone coronary artery bypass surgery.
effects of magnesium sulfate on onset and duration of low dose rocuronium

Conditions: Observation of Neuromuscular Block; Intubation Condition; Surgical Condition

Summary: this study aims to evaluate effects of magnesium sulfate on onset and duration of low dose rocuronium, intubation condition and surgical condition.


Eligibility criteria:
inclusion criteria: * 18-75 yr american society of anesthesiologists physical status 1 or 2, bmi of 20-24.9 kg/m2 scheduled for elective laryngeal microsurgery exclusion criteria: * severe respiratory or cardiac disease hepatic or renal function impairment neuromuscular disease on medications affecting neuromuscular function with known allergy to the drugs

Keywords: magnesium sulfate, rocuronium
schistosomiasis in formal and non-formal schools in uganda: implications for control programmes

Conditions: Schistosomiasis; Helminthiasis; Anaemia

Summary: current efforts to control schistosomiasis and soil-transmitted helminthes infections focus on the school-age population, and school-based treatment delivery programs offer a major cost advantages because of the use of the existing school infrastructure and the fact that schoolchildren are accessible through schools. however, in many developing countries, large numbers of school-age children are not in school and this has raised questions about the effectiveness of school-based programs in reaching non-enrolled children. increasingly, the non-formal education sector is providing a growing solution to the problem of poor enrolment in basic education, especially in sub-saharan africa, and has recently been used to deliver praziquantel as part of a national schistosomiasis control program in uganda. however, it is unclear how effective this program has been in reaching children who attend non-formal schools and whether the program has been reaching children from the poorest households.

this study will compare infection and nutritional status of children enrolled in formal schools and non-formal schools, and non-enrolled children in nakasongola district in uganda, and investigate the process and impact of treatment delivered by the national control program. the study will consist of household surveys and cross-sectional parasitological and hematological surveys, with follow-up six months later. the evaluation will take place over the course of a year and will: * compare the infection and nutritional status of children enrolled in formal schools and non-formal schools, and non-enrolled children in nakasongola district, uganda * compare programmatic process indicators, including enrolment rates, attendance rates, access to water and sanitation, treatment coverage in formal and non-formal schools * investigate the impact of treatment on intensity of infection and reinfection rates in formal and non-formal schools.

Eligibility criteria:
inclusion criteria: * school children in grad 1 and 2

Keywords: schistosomiasis helminthes anaemia